CSI Market
Sign In | Register

United Therapeutics (UTHR) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access UTHR Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how United Therapeutics funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income607.90
Depreciation & amortization46.80
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use4.90
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories121.90
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation77.30
Income (Loss) from Equity Method Investments0.00
Loss Contingency, Loss in Period0.00
Provision For Doubtful Accounts And Inventory Writedown-
License Costs Incurred But Not Paid-
Impairment Of Investments In Privately Held Companies-
Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount-
Tangible Asset Impairment Charges-
Equity Securities Fv Ni Unrealized Gain Loss61.60
Income taxes0.00
Gain on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-39.90
Increase (Decrease) in Accounts Payable and Accrued Liabilities-16.70
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital77.10
Other Noncash Income (Expense)-56.80
Other net0.00
Payments for (Proceeds from) Other Operating Activities-45.60
Discontinued operations0.00
Net Cash flow from Operating Activities776.90
Investing Activities
Capital Expenditures-208.80
Sale of Capital Items0.00
Short-term Investments Proceeds1,842.20
Payments to Acquire Available-for-sale Securities, Debt-770.80
Real Estate Investments0.00
Payments To Acquire Variable Interest Entity-
Advance Payment Related To Property Plant And Equipment-5.70
Decrease In Cash Due To Deconsolidation Of Variable Interest Entity-
Proceeds From Sale Of Equity Securities Fv Ni-
Proceeds From Equity Securities Without Readily Determinable Fair Value-
Payments To Acquire Equity Securities Without Readily Determinable Fair Value-25.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-31.40
Discontinued operations0.00
Net Cash Flow from Investing Activities831.20
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-3.40
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1,299.80
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-58.80
Other net0.00
Payments Of Convertible Debt Hedge And Warrants Net-
Payment For Accelerated Share Repurchase Transaction Cost-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1,362.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow568.10
Total Cash Flow246.10
4 historic quarters locked

Sign in to unlock the full United Therapeutics cash flow history.

Sign In Create Free Account

About United Therapeutics Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001082554-26-000027

Figures are derived from filed reports and may be restated. Historical data is subject to revision.